- Product Details
Keywords
- Parecoxib
- Parecoxib API
- 99% Parecoxib API
Quick Details
- ProName: Parecoxib Sodium API
- CasNo: 198470-85-8
- Molecular Formula: C19H17N2NaO4S
- Appearance: white powder
- Application: pharmaceutical R&D
- DeliveryTime: based on order
- PackAge: drum or as required
- Port: Shanghai
- ProductionCapacity: 100 Kilogram/Month
- Purity: 99%
- Storage: room temperature
- Transportation: Normal temperature transportation
- LimitNum: 1 Kilogram
- Valid Period: 24 months
Superiority
GMP certification
could be used for finished formulation R&D and manufacture
technical package is available for long-term cooperation
could meet the order from lab use to commercial manufacture
competitive price will be provided based on the quantity
Bocimed does not sell compounds in the period of patent protection. According to the relevant provisions of the patent law, "the act of importing, manufacturing and using patented drugs by others before the expiration of drug patents without the consent of the patentee in order to obtain the data and other information required by the drug administration department shall be not regarded as infringing the patent right".
Details
product name: Parecoxib Sodium API
CAS 198470-85-8
purity ≥ 99%
Bocimed is a technology enterprise specializing in pharmaceutical research, which was established in Zhangjiang Pharmaceutical Valley of Shanghai in 2012. Bocimed has Zhangjiang R & D headquarter, Lingang production base and Chengdu clinical subsidiary. With the unique platform advantages of solubilization technology, sustained-release technology and nanotechnology, the company is committed to become a leading enterprise in the development and production of innovative and special preparations, and realize the vision of bringing better drugs to the world.
Bocimed does not sell compounds in the period of patent protection. According to the relevant provisions of the patent law, "the act of importing, manufacturing and using patented drugs by others before the expiration of drug patents without the consent of the patentee in order to obtain the data and other information required by the drug administration department shall be not regarded as infringing the patent right".